Company intelligence / Profile preview

Aestas Pharma Inc.

Durham, North Carolina, United Statesaestaspharma.com ↗

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

Aestas Pharma develops novel diagnostic imaging and disease-modifying therapeutic agents for the early detection, treatment, and potential reversal of Alzheimer’s and Parkinson’s diseases. Their lead programs target aberrant CDK5 activity, a key upstream event in neurodegenerative pathology. The company has received SBIR Phase I funding to develop a first-in-class PET imaging agent for early Alzheimer’s detection; all programs are currently preclinical.[1][2][3][4]

Therapeutic areas: Neurology
Modalities: Small moleculesPeptidesDiagnostic imaging agents
Industry: Biotech

Drug pipeline

1 asset

AP-251

Pre-clinical

Indications: Alzheimer's disease

Partnerships

{"partner": "National Institutes of Health/National Institute of Neurological Disorders & Stroke", "type": "Licensing/Originator"}[2][4]{"partner": "NIH/NIA via SBIR grant"}[4]

Beyond the preview

Go deeper on Aestas Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aestas Pharma Inc..

Explore the full profile